Tuberculosis biomarkers: From diagnosis to protection

Infectious Disease Reports

Volumn 8, Issue 2, 2016, Pages 24-32

  Goletti, Delia ^a   Petruccioli, Elisa ^a   Joosten, Simone A ^b   Ottenhoff, Tom H M ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Tuberculosis

Indexed keywords

BACTERIAL DNA; BCG VACCINE; BIOLOGICAL MARKER; CD38 ANTIGEN; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEME OXYGENASE 1; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HLA DR ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; KI 67 ANTIGEN; LIPOARABINOMANNAN; MATRIX METALLOPROTEINASE; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; TUBERCULOSTATIC AGENT; VASCULOTROPIN; VOLATILE ORGANIC COMPOUND;

ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTECTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; TUBERCULOSIS RAPID TEST;

EID: 84992745426     PISSN: None     EISSN: 20367449     Source Type: Journal    
DOI: 10.4081/idr.2016.6568     Document Type: Article

References (163)

1. WHO. Global tuberculosis report. 2015. Available from: http://www.who.int/tb/publications/global_report/en/.
2. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010;50:S201-7.
3. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50.
4. Cantini F, Goletti D. Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence. J Rheumatol Suppl 2014;91:1-3.
5. Cantini F, Lubrano E, Marchesoni A, et al. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. Int J Rheum Dis 2015 Jul 14. [Epub ahead of print]
6. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-87.
7. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014;371:1599-608.
8. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014;371:1588-98.
9. Lagrange PH, Thangaraj SK, Dayal R, et al. A toolbox for tuberculosis diagnosis: an Indian multicentric study (2006-2008): microbiological results. PLoS One 2012;7: e43739.
10. Lagrange PH, Thangaraj SK, Dayal R, et al. A toolbox for tuberculosis (TB) diagnosis: an Indian multicentric study (2006-2008). Evaluation of QuantiFERON-TB gold in tube for TB diagnosis. PLoS One 2013;8:e73579.
11. Lagrange PH, Thangaraj SK, Dayal R, et al. A toolbox for tuberculosis (TB) diagnosis: an Indian multi-centric study (2006-2008); evaluation of serological assays based on PGL-Tb1 and ESAT-6/CFP10 antigens for TB diagnosis. PLoS One 2014;9:e96367.
12. Xia H, Wang X, Li F, et al. Diagnostic values of the QuantiFERON-TB Gold In-tube assay carried out in China for diagnosing pulmonary tuberculosis. PLoS One 2015;10:e0121021.
13. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-15.
14. Davies PD, Pai M. The diagnosis and misdiagnosis of tuberculosis. Int J Tuberc Lung Dis 2008;12:1226-34.
15. Bacakoglu F, Basoglu OK, Cok G, et al. Pulmonary tuberculosis in patients with diabetes mellitus. Respiration 2001;68:595-600.
16. Walzl G, Ronacher K, Hanekom W, et al. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011;11:343-54.
17. Denkinger CM, Kik SV, Cirillo DM, et al. Defining the needs for next generation assays for tuberculosis. J Infect Dis 2015;211:S29-38.
18. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
19. Wallis RS, Peppard T. Early Biomarkers and regulatory innovation in multidrugresistant tuberculosis. Clin Infect Dis 2015;61:S160-3.
20. Ottenhoff TH. Overcoming the global crisis: yes, we can, but also for TB. ? Eur J Immunol 2009;39:2014-20.
21. Ottenhoff TH, Ellner JJ, Kaufmann SH. Ten challenges for TB biomarkers. Tuberculosis (Edinb) 2012;92:S17-20.
22. Cliff JM, Cho JE, Lee JS, et al. Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment. J Infect Dis 2016;213:485-95.
23. Joosten SA, Goeman JJ, Sutherland JS, et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun 2012;13: 71-82.
24. Kaforou M, Wright VJ, Oni T, et al. Detection of tuberculosis in HIV-infected and-uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med 2013;10: e1001538.
25. Cannas A, Goletti D, Girardi E, al. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2008;12:146-51.
26. da Cruz HL, de Albuquerque Montenegro R, de Araujo Lima JF, et al. Evaluation of a nested-PCR for mycobacterium tuberculosis detection in blood and urine samples. Braz J Microbiol 2011;42:321-9.
27. Theron G, Peter J, Calligaro G, et al. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Sci Rep 2014;4:5658.
28. Minion J, Leung E, Talbot E, et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J 2011;38:1398-405.
29. Mukundan H, Price DN, Goertz M, et al. Understanding the interaction of Lipoarabinomannan with membrane mimetic architectures. Tuberculosis (Edinb) 2012;92:38-47.
30. Chan CE, Gotze S, Seah GT, et al. The diagnostic targeting of a carbohydrate virulence factor from M. tuberculosis. Sci Rep 2015;5:10281.
31. Hamasur B, Bruchfeld J, van Helden P, et al. A sensitive urinary lipoarabinomannan test for tuberculosis. PLoS One 2015;10:e0123457.
32. Aceti A, Zanetti S, Mura MS, et al. Identification of HIV patients with active pulmonary tuberculosis using urine based polymerase chain reaction assay. Thorax 1999;54:145-6.
33. Nakiyingi L, Moodley VM, Manabe YCet al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr 2014;66:270-9.
34. Lawn SD, Kerkhoff AD, Burton R, et al. Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB/RIF: a prospective cohort in South Africa. BMC Med 2015;13:192-015-0432-2.
35. Ronning DR, Klabunde T, Besra GS, et al. Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat Struct Biol 2000;7:141-6.
36. Armitige LY, Jagannath C, Wanger AR, Norris SJ. Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect Immun 2000;68:767-78.
37. Bentley-Hibbert SI, Quan X, Newman T, et al. Pathophysiology of antigen 85 in patients with active tuberculosis: antigen 85 circulates as complexes with fibronectin and immunoglobulin G. Infect Immun 1999;67:581-8.
38. Kashyap RS, Rajan AN, Ramteke SS, et al. Diagnosis of tuberculosis in an Indian population by an indirect ELISA protocol based on detection of antigen 85 complex: a prospective cohort study. BMC Infect Dis 2007;7:74.
39. Kunnath-Velayudhan S, Salamon H, Wang HY, et al. Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad Sci USA 2010;107: 14703-8.
40. WHO. Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. Available from: http://apps. who.int/iris/bitstream/10665/44652/1/978 9241502054_eng.pdf
41. Huang J, Jiao J, Xu W, et al. miR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3. Mol Med Rep 2015;12:7102-8.
42. Miotto P, Mwangoka G, Valente IC, et al. miRNA signatures in sera of patients with active pulmonary tuberculosis. PLoS One 2013;8:e80149.
43. Esterhuyse MM, Weiner J 3rd, Caron E, et al. Epigenetics and proteomics join transcriptomics in the quest for tuberculosis biomarkers. MBio 2015;6:e01187-15.
44. Ren N, Gao G, Sun Y, et al. MicroRNA signatures from multidrugresistant Mycobacterium tuberculosis. Mol Med Rep 2015;12:6561-7.
45. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-7.
46. Lesho E, Forestiero FJ, Hirata MH, et al. Transcriptional responses of host peripheral blood cells to tuberculosis infection. Tuberculosis (Edinb) 2011;91:390-9.
47. Maertzdorf J, Ota M, Repsilber D, et al. Functional correlations of pathogenesisdriven gene expression signatures in tuberculosis. PLoS One 2011;6:e26938.
48. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011;12:15-22.
49. Bloom CI, Graham CM, Berry MP, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 2013;8:e70630.
50. Walter ND, Dolganov GM, Garcia BJ, et al. Transcriptional adaptation of drug-tolerant mycobacterium tuberculosis during treatment of human tuberculosis. J Infect Dis 2015;212:990-8.
51. Maertzdorf J, Weiner J 3rd, Mollenkopf HJ, et al. Common patterns and diseaserelated signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci USA 2012;109:7853-8.
52. Joosten SA, Fletcher HA, Ottenhoff TH. A helicopter perspective on TB biomarkers: pathway and process based analysis of gene expression data provides new insight into TB pathogenesis. PLoS One 2013;8:e73230.
53. Anderson ST, Kaforou M, Brent AJ, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 2014;370:1712-23.
54. Chegou NN, Detjen AK, Thiart L, et al. Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a highburden setting. PLoS One 2013;8:e64226.
55. Lighter J, Rigaud M, Huie M, et al. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int J Tuberc Lung Dis 2009;13:731-6.
56. Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma? PLoS One 2008;3:e3901.
57. Azzurri A, Sow OY, Amedei A, et al. IFNgamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005;7:1-8.
58. Petrone L, Cannas A, Aloi F, et al. Blood or urine IP-10 cannot discriminate between active tuberculosis and respiratory diseases different from tuberculosis in children. Biomed Res Int 2015;2015:589471.
59. Corstjens PL, Tjon Kon Fat EM, de Dood CJ, et al. Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa. Clin Biochem 2016;49:22-31.
60. Corstjens PL, Zuiderwijk M, Tanke HJ, et al. A user-friendly, highly sensitive assay to detect the IFN-gamma secretion by T cells. Clin Biochem 2008;41:44044.
61. Bobosha K, Tjon Kon Fat EM, van den Eeden SJ, et al. Field-evaluation of a new lateral flow assay for detection of cellular and humoral immunity against Mycobacterium leprae. PLoS Negl Trop Dis 2014;8:e2845.
62. Geluk A, van Meijgaarden KE, Wilson L, et al. Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. J Clin Immunol 2014;34:245-55.
63. Khadge S, Banu S, Bobosha K, et al. Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal. BMC Infect Dis 2015;15:477-015-1128-0.
64. Cannas A, Calvo L, Chiacchio T, et al. IP-10 detection in urine is associated with lung diseases. BMC Infect Dis 2010;10:333-2334-10-333.
65. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-50.
66. Ciuffreda D, Comte D, Cavassini M, et al. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol 2008;38:2665-77.
67. Duvall MG, Precopio ML, Ambrozak DA, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008;38:350-63.
68. Petrone L, Vanini V, Petruccioli E, et al. Polyfunctional specific response to echinococcus granulosus associates to the biological activity of the cysts. PLoS Negl Trop Dis 2015;9:e0004209.
69. Harari A, Rozot V, Bellutti Enders F, et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011;17:372-6.
70. Petruccioli E, Petrone L, Vanini V, et al. IFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis. J Infect 2013;66:475-86.
71. Pollock KM, Whitworth HS, Montamat-Sicotte DJ, et al. T-cell immunophenotyping distinguishes active from latent tuberculosis. J Infect Dis 2013;208:952-68.
72. Chiacchio T, Petruccioli E, Vanini V, et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J Infect 2014;69:533-45.
73. Day CL, Abrahams DA, Lerumo L, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 2011;187:2222-32.
74. Caccamo N, Guggino G, Joosten SA, et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010;40:2211-20.
75. Goletti D, Butera O, Bizzoni F, et al. Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. J Infect Dis 2006;194:984-92.
76. Butera O, Chiacchio T, Carrara S, et al. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect Dis 2009;9:182-2334-9-182.
77. Petruccioli E, Petrone L, Vanini V, et al. Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. J Infect 2015;71:526-33.
78. Wang X, Cao Z, Jiang J, et al. Association of mycobacterial antigen-specific CD4(+) memory T cell subsets with outcome of pulmonary tuberculosis. J Infect 2010;60:133-9.
79. Geldmacher C, Ngwenyama N, Schuetz A, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 2010;207:2869-81.
80. Portevin D, Moukambi F, Clowes P, et al. Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. Lancet Infect Dis 2014;14:931-8.
81. Nikitina IY, Kondratuk NA, Kosmiadi GA, et al. Mtb-specific CD27low CD4 T cells as markers of lung tissue destruction during pulmonary tuberculosis in humans. PLoS One 2012;7:e43733.
82. Adekambi T, Ibegbu CC, Kalokhe AS, et al. Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis. PLoS One 2012;7:e36046.
83. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun 2016;7:11290.
84. Tientcheu LD, Maertzdorf J, Weiner J, et al. Differential transcriptomic and metabolic profiles of M. africanum and M. tuberculosis-infected patients after, but not before, drug treatment. Genes Immun 2015;16:347-55.
85. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006;368:1012-21.
86. Liu Q, Chen X, Hu C, et al. Serum protein profiling of smear-positive and smearnegative pulmonary tuberculosis using SELDI-TOF mass spectrometry. Lung 2010;188:15-23.
87. Phillips M, Basa-Dalay V, Bothamley G, et al. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb) 2010;90:145-51.
88. Neyrolles O, Hernandez-Pando R, Pietri-Rouxel F, et al. Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS One 2006;1:e43.
89. Das B, Kashino SS, Pulu I, et al. CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med 2013;5:170ra13.
90. Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013;1:462-70.
91. Nikolayevskyy V, Miotto P, Pimkina E, et al. Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease. Tuberculosis (Edinb) 2015;95:179-85.
92. Riou C, Perez Peixoto B, Roberts L, et al. Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One 2012;7:e36886.
93. Andrade BB, Pavan Kumar N, Mayer-Barber KD, et al. Plasma heme oxygenase-1 levels distinguish latent or successfully treated human tuberculosis from active disease. PLoS One 2013;8:e62618.
94. Andrade BB, Pavan Kumar N, Amaral EP, et al. Heme oxygenase-1 regulation of matrix metalloproteinase-1 expression underlies distinct disease profiles in tuberculosis. J Immunol 2015;195:2763-73.
95. Nahid P, Bliven-Sizemore E, Jarlsberg LG, et al. Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis (Edinb) 2014;94:187-96.
96. Tonby K, Ruhwald M, Kvale D, Dyrhol-Riise AM. IP-10 measured by dry plasma spots as biomarker for therapy responses in Mycobacterium tuberculosis infection. Sci Rep 2015;5:9223.
97. den Hertog AL, Montero-Martin M, Saunders RL, et al. Cytokine kinetics in the first week of tuberculosis therapy as a tool to confirm a clinical diagnosis and guide therapy. PLoS One 2015;10: e0129552.
98. Kriel M, Lotz JW, Kidd M, Walzl G. Evaluation of a radiological severity score to predict treatment outcome in adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 2015;19:1354-60.
99. Rizzi EB, Schinina' V, Cristofaro M, et al. Detection of pulmonary tuberculosis: comparing MR imaging with HRCT. BMC Infect Dis 2011;11:243-2334-11-243.
100. Chen RY, Dodd LE, Lee M, et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med 2014;6: 265ra166.
101. du Plessis N, Loebenberg L, Kriel M, et al. Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med 2013;188:724-32.
102. El Daker S, Sacchi A, Tempestilli M, et al. Granulocytic myeloid derived suppressor cells expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level. PLoS One 2015;10:e0123772.
103. Carrara S, Vincenti D, Petrosillo N, et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004;38:754-6.
104. Latorre I, Altet N, de Souza-Galvao M, et al. Specific Mycobacterium tuberculosis T cell responses to RD1-selected peptides for the monitoring of anti-tuberculosis therapy. Scand J Infect Dis 2012;44:161-7.
105. Goletti D, Carrara S, Mayanja-Kizza H, et al. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC Infect Dis 2008;8:11-2334-8-11.
106. Kabeer BS, Raja A, Raman B, et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis 2011;11:135-2334-11-135.
107. Kabeer BS, Sikhamani R, Raja A. Comparison of interferon gammainducible protein-10 and interferon gamma-based QuantiFERON TB Gold assays with tuberculin skin test in HIVinfected subjects. Diagn Microbiol Infect Dis 2011;71:236-43.
108. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127-35.
109. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64.
110. Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001;183:469-77.
111. Whitworth HS, Scott M, Connell DW, et al. IGRAs-the gateway to T cell based TB diagnosis. Methods 2013;61:52-62.
112. Mahairas GG, Sabo PJ, Hickey MJ, et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996;178:1274-82.
113. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356:1099-104.
114. Gey van Pittius NC, Sampson SL, Lee H, et al. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evol Biol 2006;6:95.
115. Arend SM, Andersen P, van Meijgaarden KE, et al. Detection of active tuberculosis infection by T cell responses to earlysecreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis 2000;181:1850-4.
116. Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl 2014;91: 24-31.
117. Barcellini L, Borroni E, Brown J, Brunetti E, Codecasa L, Cugnata F, et al. First independent evaluation of QuantiFERON-TB Plus performance. Eur Respir J 2016 Feb 11.
118. Sester M, van Leth F, Bruchfeld J, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014;190:1168-76.
119. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012;142:63-75.
120. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009;7:845-55.
121. Ruhwald M, Petersen J, Kofoed K, et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS One 2008;3:e2858.
122. Goletti D, Raja A, Syed Ahamed Kabeer B, et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS One 2010;5:e12577.
123. Goletti D, Raja A, Ahamed Kabeer BS, et al. IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J Infect 2010;61:133-43.
124. Vanini V, Petruccioli E, Gioia C, et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect 2012;65:49-59.
125. Wergeland I, Pullar N, Assmus J, et al. IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. J Infect 2015;70:381-91.
126. Mihret A, Bekele Y, Bobosha K, et al. Plasma cytokines and chemokines differentiate between active disease and nonactive tuberculosis infection. J Infect 2013;66:357-65.
127. Djoba Siawaya JF, Beyers N, van Helden P, Walzl G. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin Exp Immunol 2009;156:69-77.
128. Feruglio SL, Troseid M, Damas JK, et al. Soluble markers of the Toll-like receptor 4 pathway differentiate between active and latent tuberculosis and are associated with treatment responses. PLoS One 2013;8:e69896.
129. Arlehamn CL, Seumois G, Gerasimova A, et al. Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features. J Immunol 2014;193:2931-40.
130. Goletti D, Butera O, Vanini V, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010;36:135-42.
131. Black GF, Thiel BA, Ota MO, et al. Immunogenicity of novel DosR regulonencoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 2009;16:1203-12.
132. Leyten EM, Lin MY, Franken KL, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006;8:2052-60.
133. Chiacchio T, Petruccioli E, Vanini V, et al. Higher frequency of T-cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. PLoS One 2011;6:e27539.
134. Schuck SD, Mueller H, Kunitz F, et al. Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection. PLoS One 2009;4:e5590.
135. Hougardy JM, Schepers K, Place S, et al. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS One 2007;2:e926.
136. Delogu G, Chiacchio T, Vanini V, et al. Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS One 2011;6:e18315.
137. Corbiere V, Pottier G, Bonkain F, et al. Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PLoS One 2012;7:e43285.
138. Wyndham-Thomas C, Corbiere V, Dirix V, et al. Key role of effector memory CD4+ T lymphocytes in a short-incubation heparin-binding hemagglutinin gamma interferon release assay for the detection of latent tuberculosis. Clin Vaccine Immunol 2014;21:321-8.
139. Wyndham-Thomas C, Dirix V, Schepers K, et al. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold in-tube. BMC Infect Dis 2015;15:59-015-0796-0.
140. Lindenstrom T, Agger EM, Korsholm KS, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009;182: 8047-55.
141. Derrick SC, Yabe IM, Yang A, Morris SL. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011;29:2902-9.
142. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010;182:1073-9.
143. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-8.
144. Ottenhoff TH. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 2012;20:419-28.
145. Wuthrich M, Gern B, Hung CY, et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J Clin Invest 2011;121:554-68.
146. Chen K, McAleer JP, Lin Y, et al. Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity 2011;35:997-1009.
147. Carlson MJ, West ML, Coghill JM, et al. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009;113:1365-74.
148. Muranski P, Borman ZA, Kerkar SP, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011;35:972-85.
149. Kryczek I, Zhao E, Liu Y, et al. Human TH17 cells are long-lived effector memory cells. Sci Transl Med 2011;3:104ra100.
150. Zhang Y, Joe G, Hexner E, et al. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med 2005;11:1299-305.
151. Zhao DM, Yu S, Zhou X, et al. Constitutive activation of Wnt signaling favors generation of memory CD8 T cells. J Immunol 2010;184:1191-9.
152. Gattinoni L, Zhong XS, Palmer DC, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 2009;15:808-13.
153. Freches D, Korf H, Denis O, et al. Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. Immunology 2013;140:220-31.
154. Gopal R, Monin L, Slight S, et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog 2014;10:e1004099.
155. Gopal R, Lin Y, Obermajer N, et al. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol 2012;42:364-73.
156. Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007;8:369-77.
157. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009;457:557-61.
158. Godfrey DI, Uldrich AP, McCluskey J, et al. The burgeoning family of unconventional T cells. Nat Immunol 2015;16:1114-23.
159. Dieli F, Ivanyi J, Marsh P, et al. Characterization of lung gamma delta T cells following intranasal infection with Mycobacterium bovis bacillus Calmette-Guerin. J Immunol 2003;170:463-9.
160. Shen Y, Zhou D, Qiu L, et al. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 2002;295:2255-8.
161. Dieli F, Troye-Blomberg M, Ivanyi J, et al. Vgamma9/Vdelta2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur J Immunol 2000;30:1512-19.
162. Dieli F, Troye-Blomberg M, Ivanyi J, et al. Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes. J Infect Dis 2001;184:1082-5.
163. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012;8:e1002607.